Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

CARRA

Mary Desmond Pinkowish  |  Issue: May 2011  |  May 16, 2011

To date, at least 11 CARRA studies and 16 abstracts have been published. Recently, findings of the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) appeared in Arthritis & Rheumatism, and this study, sponsored by NIAMS and, although the study is closed to enrollment, tissue samples can be used for ongoing translational studies and novel ways of looking at the data are being pursued.2 Dr. Ilowite notes the seminal trials of early aggressive therapy in JIA, and a study of the safety and effectiveness of rilonacept in systemic JIA. See Table 1 for a complete listing of CARRA studies.

The CARRA Registry

Building on CARRA, the organization of pediatric rheumatologists, is CARRAnet, the network of sites where these investigators work. The first project for CARRAnet is the CARRA Registry, an observational retrospective and prospective cohort study enrolling pediatric patients with major rheumatic diseases who are being followed at participating study sites. But with human and financial resources strained at individual sites, CARRA has had to find outside means to support this endeavor.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We would like to be able to add, as an organizational support, more infrastructure that is directly usable by sites and that will help them accomplish research. We have done that to some degree with the CARRAnet grant, which was awarded by the National Institutes of Health (NIH) with funds from the American Recovery and Reinvestment Act (ARRA) of 2009,” says Dr. Schanberg. The funds, totaling over $6 million, will enable CARRAnet to bolster its informatics capabilities at individual sites, allowing them to enter patients in the CARRAnet registry. The grant was awarded to Duke University, where Dr. Schanberg one of the lead investigators along with Dr. Sandborg, Dr. Ilowite, and Carol Wallace, MD, at Seattle Children’s Hospital. The grant is administered by the Duke Clinical Research Institute (DCRI).

The goal of CARRAnet is the creation of a unifying, scalable informatics infrastructure for CARRA sites. According to DCRI senior project leader Kathleen Fox, the infrastructure currently under development by CARRAnet will increase operational efficiencies at each CARRA site. “You systematically build on operational processes you agree to at the beginning, and these become less burdensome as you add more projects,” says Fox. “For example, we’ve developed master site agreements. The basic legalese is already agreed upon. When there is a new project, we just add an addendum, rather than renegotiating right from the beginning,” she says. Funding for the CARRAnet grant continues through August 2011 with the possibility of an extension through August 2012.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 6 7 8 | Single Page
Share: 

Filed under:ConditionsOther Rheumatic ConditionsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:CARRAChildhood Arthritis and Rheumatology Research AllianceJIAJuvenile idiopathic arthritisLupusPediatric

Related Articles

    The Future of Pediatric Rheumatology Grounded in Evolution of Childhood Arthritis and Rheumatology Research Alliance

    December 15, 2016

    Pediatric rheumatology was formally recognized as a specialty in 1991 by the American Board of Pediatrics. Prior to this time, children with rheumatic diseases were treated by a hodgepodge of providers. In addition to providers who had training as pediatric rheumatologists, general pediatricians, adult rheumatologists, allergist-immunologists, orthopedists, pediatric infectious disease specialists and others treated children…

    Oksana Kuzmina/shutterstock.comx

    Environmental Factors in Pediatric Systemic Autoimmune Diseases

    March 20, 2017

    Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

    2013 ACR/ARHP Annual Meeting: Better Care for Pediatric Rheumatology Patients On Horizon

    February 1, 2014

    A robust workforce, flourishing clinical trials, broad patient registries, and consensus treatment protocols contribute to improvements for the subspecialty

    An Overview of Pediatric, Noninfectious Uveitis

    October 18, 2018

    Uveitis is an inflammation of the uvea, which comprises the iris, ciliary body and choroid. Uveitis can lead to ocular damage and complete visual loss. Noninfectious etiologies for uveitis are the most common in the U.S.1 The estimated incidence of uveitis ranges from 25–52 per 100,000 in adults and five per 100,000 in children. The…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences